QT Imaging Holdings, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. QT Imaging Holdings completed its business combination with GigCapital5 on March 4, 2024; the transaction was accounted for as a reverse recapitalization. Prior-period share and per-share figures were retrospectively adjusted, and the results principally reflect QT Imaging’s operations.
Business context and results
The company develops and commercializes medical imaging systems using low-frequency sound. Its current product is the QT Breast Scanner. It reported selling three scanners in Q1 2024, compared with none in Q1 2023. The company says its breast scanner received FDA 510(k) clearance in 2017 for the described use; expanded indications and future products remain subject to regulatory and commercial risks.
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $1.36 million | $7,564 |
| Gross profit (loss) | $760,080 | ($39,013) |
| Gross margin | 55.8% | Not meaningful |
| Operating expenses | $6.34 million | $1.71 million |
| Loss from operations | ($5.58 million) | ($1.75 million) |
| Net loss | ($4.30 million) | ($1.88 million) |
| Operating cash flow | ($5.98 million) | ($993,000) |
Revenue growth was primarily from three scanner sales; product revenue was $1.31 million and service revenue was $56,043. Two customers accounted for 99% of quarterly revenue, and one customer represented 93% of receivables at quarter-end. Management attributed most of the $4.40 million increase in selling, general and administrative expense to $3.94 million of business-combination transaction expenses. Research and development expense rose 52% to $643,000.
Financial position, liquidity and financing
- At March 31, cash was $5.62 million and restricted cash was $20,000, versus cash and restricted cash totaling $185,000 at year-end. Current assets were $11.43 million and current liabilities $4.37 million, or approximately $7.06 million of working capital.
- Inventory was $4.12 million. Total liabilities were $17.77 million, against total assets of $12.86 million; stockholders’ deficit was $4.91 million. Operating lease liabilities totaled $1.34 million.
- Financing activities provided $11.43 million, including proceeds associated with the Yorkville advance and Cable Car loan, merger proceeds, and a stock subscription. The company used $5.98 million in operating activities and reported no investing cash flow.
- Yorkville’s $10 million pre-paid advance is due 15 months after issuance, bears 6% interest (18% following an event of default), and is convertible into common stock. The quarter-end carrying amount of the advance was affected by issuance costs and a separately recognized derivative. The Cable Car loan was $1.5 million at issuance, has a 13-month maturity, and may be convertible in certain circumstances.
- Related-party notes payable were $5.41 million at quarter-end. The filing also reports $3.33 million of long-term debt and $131,000 of current maturities; debt carrying values are affected by discounts and other accounting adjustments.
- Management believes available cash and financing arrangements will fund its current operating plan for at least 12 months. It also expects continued operating losses and negative operating cash flow and says additional capital may be needed; future financing may be unavailable on acceptable terms.
Changes, outlook and notable items
- Net loss increased by $2.42 million year over year, while operating loss worsened by $3.83 million. The reported net loss was partly offset by a $2.98 million gain from the change in fair value of the Yorkville-related derivative; the earnout liability generated a $1.06 million fair-value expense. These are valuation items, not operating revenue.
- The March 2024 business combination produced only $1.24 million of net cash proceeds after redemptions, transaction costs, and repayment of related-party notes, and the company assumed substantial net liabilities.
- The company has a non-binding Canon letter of intent and a feasibility study agreement running through December 2024. Canon is evaluating business, technical, clinical, manufacturing, regulatory, and market considerations. A definitive OEM agreement is only a stated target for the second half of 2024, not a completed arrangement. The company had delivered one scanner to an NXC customer as of March 31.
- No numerical revenue or earnings guidance was provided. Management expects research and development, sales and marketing, and public-company costs to rise. It says future funding needs depend on commercialization, regulatory work, manufacturing, and sales growth.
- Potential dilution is significant: 46.4 million shares were reserved for warrants, the Yorkville advance, earnouts, the Cable Car loan, convertible notes, and the equity plan, compared with 21.4 million common shares outstanding at March 31. The filing describes a possible $50 million SEPA commitment, subject to conditions and limitations; access to the full amount is not assured. The warrant exercise price was subsequently adjusted to $2.30 per share.
- Management concluded disclosure controls were effective, but identified material weaknesses in internal control over financial reporting: insufficient segregation of duties and technical accounting for certain material transactions. Remediation is underway; management reported no Q1 financial-statement misstatements resulting from these weaknesses.
- The company reported no material pending legal proceeding known to management. Key stated risks include continued losses and financing needs, customer and supplier concentration, market adoption, reimbursement, regulatory clearance, cybersecurity and data protection, and possible dilution.
Important facts for investors to verify
- Whether scanner shipments, repeat orders, and customer diversification can support sustained revenue growth and improved margins.
- Cash burn and liquidity after quarter-end, including the actual availability and conditions of SEPA funding and the timing and terms of debt repayments.
- The Yorkville note’s conversion mechanics, derivative accounting, and potential share issuance, as well as warrant repricing and other dilution sources.
- Progress and binding terms, if any, for the Canon OEM relationship, and the regulatory clearances required for planned indications and products.
- Whether the company remediates both internal-control material weaknesses and sustains reliable financial reporting.